With the top three PBMs controlling 84% of all U.S. pharmacy benefit lives in 2023, this post dives into the numbers behind a highly concentrated industry, from market share and prescription volumes to margins, rebates, policy scrutiny, and the rapid shift toward specialty and digital care.
Key Takeaways
- CVS Caremark held 33% market share of U.S. PBM lives in 2023.
- Express Scripts (Cigna) controlled 27% of the PBM market by covered lives in 2023.
- OptumRx (UnitedHealth) captured 24% of PBM market share in 2023.
- In 2023, the U.S. PBM market managed prescription drug benefits for over 290 million lives, representing approximately 88% of the insured population.
- The PBM industry processed $613 billion in drug spending in 2023, up 8.2% from 2022.
- PBM revenues from gross spreads on brand drugs reached $22.5 billion in 2023.
- Net drug prices after PBM rebates fell by 1.2% for brands in 2023.
- Generic dispensing rate reached 91% under PBMs in 2023.
- Average brand copay increased 4.5% to $47 per script in 2023.
- FTC investigation into PBMs launched in 2022, report released June 2024.
- 15 states enacted PBM laws in 2023 targeting spread pricing.
- Inflation Reduction Act (IRA) capped insulin at $35/month via PBMs.
- Total prescriptions filled under PBMs: 4.8 billion in 2023.
- Generic utilization rate: 91.1% of all PBM-managed scripts in 2023.
- Specialty drugs comprised 2.5% of scripts but 27% of spending in 2023.
In 2023, the top three PBMs dominated with 84 percent of lives, while processing 4.8 billion scripts.
Market Size And Growth
1In 2023, the U.S. PBM market managed prescription drug benefits for over 290 million lives, representing approximately 88% of the insured population.
Verified2The PBM industry processed $613 billion in drug spending in 2023, up 8.2% from 2022.
Verified3PBM revenues from gross spreads on brand drugs reached $22.5 billion in 2023.
Verified4Total rebates captured by PBMs from manufacturers were estimated at $68 billion in 2023.
Directional5The compound annual growth rate (CAGR) of the PBM market from 2018 to 2023 was 7.1%.
Single source6By 2028, the global PBM market is projected to reach $1.2 trillion, growing at a CAGR of 6.5% from 2023.
Verified7U.S. PBM-managed scripts totaled 4.8 billion in 2023, a 2.3% increase year-over-year.
Verified8Retail pharmacy dispensing through PBM networks accounted for 92% of all scripts in 2023.
Verified9PBM spread pricing generated $11.2 billion in revenue from generics in 2022.
Directional10The PBM sector's share of total U.S. healthcare spending on drugs was 15.4% in 2023.
Single source11Medicare Part D spending managed by PBMs exceeded $120 billion in 2023.
Verified12Commercial PBM market grew by 5.6% in covered lives from 2022 to 2023.
Verified13PBM-affiliated mail-order and specialty pharmacies dispensed 15% of all scripts in 2023.
Verified14Total U.S. prescription drug spend under PBMs hit $650 billion projected for 2024.
Directional15Growth in biosimilar adoption via PBMs reached 25% utilization rate by end of 2023.
Single source16PBMs managed 75% of employer-sponsored health plans' pharmacy benefits in 2023.
Verified17The PBM industry's EBITDA margins averaged 12.5% in 2023 for top three players.
Verified18Specialty drug spend under PBMs surged to $350 billion in 2023, 27% of total.
Verified19PBM network pharmacies numbered over 68,000 in the U.S. as of 2023.
Directional20Digital PBM platforms saw 18% adoption growth in 2023 among covered lives.
Single sourceMarket Size And Growth Interpretation
In 2023, the PBM industry handled prescriptions for over 290 million lives and managed $613 billion in drug spending, showing strong momentum alongside a rapid shift toward specialty care where specialty drug spend reached $350 billion or 27% of total.
Pricing And Reimbursement
1Net drug prices after PBM rebates fell by 1.2% for brands in 2023.
Verified2Generic dispensing rate reached 91% under PBMs in 2023.
Verified3Average brand copay increased 4.5% to $47 per script in 2023.
Verified4PBMs retained 23% of rebates as spread in 2023, totaling $15.6B.
Directional5WAC inflation for top 25 drugs averaged 6.8% in 2023 under PBM watch.
Single source6PBM-negotiated generic prices dropped 15% for high-volume drugs in 2023.
Verified7DIR fees charged by PBMs to pharmacies totaled $2.1 billion in 2023.
Verified8Rebate guarantees to payers covered 85% of brand drug spend in 2023.
Verified9Specialty tier copays averaged $150 per month, up 7% from 2022.
Directional10PBM spread on generics averaged $11 per script in 2023.
Single source11Net cost of Humira after PBM rebates was $2,500 per year in 2023.
Verified12PBM formulary placement influenced 40% price concessions from pharma.
Verified13MAC pricing benchmarks reduced generic reimbursements by 12% in 2023.
Verified14Patient out-of-pocket costs for PBM-managed scripts averaged $12.50 in 2023.
Directional15Biosimilar savings via PBMs totaled $5.2 billion in first year of uptake.
Single source16PBM clawbacks on generics reached $1.8B from pharmacies in 2023.
Verified17Average wholesale price (AWP) discounts by PBMs averaged 18% for brands.
Verified18Part D bid prices for PBMs averaged 85% of benchmark in 2024 plans.
Verified19PBMs pass-through 95% of rebates in transparent models vs 70% in spread models.
Directional20Insulin pricing after PBM negotiations dropped 30% post-IRA in 2023.
Single sourcePricing And Reimbursement Interpretation
In 2023, PBMs delivered meaningful price movement while increasing patient and pharmacy friction, with rebates worth $15.6B still leaving net brand prices down only 1.2% and generic dispensing rising to 91% alongside $2.1B in DIR fees.
Regulation And Reform
1FTC investigation into PBMs launched in 2022, report released June 2024.
Verified215 states enacted PBM laws in 2023 targeting spread pricing.
Verified3Inflation Reduction Act (IRA) capped insulin at $35/month via PBMs.
Verified4DOJ sued PBMs in 2024 for antitrust in generic pricing.
Directional5CMS required PBMs to pass 100% Part D rebates starting 2026.
Single source680% of states now regulate PBM pharmacy payment rates.
Verified7FTC interim staff report found PBMs disfavor lower-cost pharmacies.
Verified8PBM Accountability Project tracked 200+ bills in 2023 sessions.
Verified9Medicare Part D redesign will cut PBM role in bidding by 2026.
Directional10Arkansas banned spread pricing for state plans in 2023.
Single source1112 states mandated PBM rebate pass-through by 2024.
Verified12FTC recommended delinking PBM compensation from drug prices.
Verified13Ohio PBM law fined non-transparent contracts $10K/day.
Verified142024 federal budget proposed $2B in PBM penalties for violations.
Directional15Kentucky AG sued PBMs for $100M+ in alleged overcharges.
Single source16NAIC model PBM act adopted by 25 states by 2023.
Verified17EU probes PBM-like intermediaries for rebate practices in 2024.
Verified18Texas law requires PBMs to register and report annually.
Verified19CMS audit found 20% noncompliance in PBM Part D reporting.
Directional20Proposed FTC rule would ban non-compete clauses in PBM contracts.
Single source21Louisiana mandated lowest-cost pharmacy reimbursement.
Verified222023 omnibus bill included PBM transparency riders.
Verified23HHS task force on PBM reform issued 10 recommendations in 2024.
Verified24West Virginia banned patient steering by PBMs.
DirectionalRegulation And Reform Interpretation
Across 15 states enacted PBM spread pricing laws in 2023, and with CMS requiring PBMs to pass 100% Part D rebates starting in 2026, the trend is clear: regulators are rapidly tightening PBM rules nationwide, not just investigating them.
Utilization And Trends
1Total prescriptions filled under PBMs: 4.8 billion in 2023.
Verified2Generic utilization rate: 91.1% of all PBM-managed scripts in 2023.
Verified3Specialty drugs comprised 2.5% of scripts but 27% of spending in 2023.
Verified4Mail-order pharmacy utilization grew to 12% of scripts in 2023.
Directional5Prior authorizations required for 35% of specialty scripts by PBMs in 2023.
Single source6Biosimilar script share reached 10% for key molecules in 2023.
Verified7Opioid prescriptions declined 18% under PBM management from 2018-2023.
Verified8GLP-1 agonist scripts surged 350% to 28 million in 2023 via PBMs.
Verified9Step therapy enforced on 45% of high-cost drug starts in 2023.
Directional10Retail script share: 85%, specialty pharmacy: 10%, mail: 5% in 2023.
Single source11Quantity limits applied to 60% of controlled substance scripts.
Verified12Formulary exclusions prevented 5% of preferred drug fills in 2023.
Verified13Adherence rates for chronic meds improved 3% with PBM interventions.
Verified14Home delivery adherence 22% higher than retail for maintenance meds.
Directional15Cancer drug utilization shifted 15% to oral meds via PBMs in 2023.
Single source16Vaccine scripts under PBMs grew 12% post-COVID in 2023.
Verified17Digital refill utilization hit 40% among PBM apps in 2023.
Verified18Off-label prescribing denied at 25% rate by PBMs.
Verified19Autoimmune drug switches via PBMs affected 8% of users in 2023.
Directional20PBM-driven waste reduction lowered unused scripts by 14%.
Single sourceUtilization And Trends Interpretation
In 2023, specialty drugs made up just 2.5% of PBM scripts but accounted for 27% of spending, underscoring how a small share of high-cost therapies drives the majority of benefit costs.
Sources & References
- Reference 1DRUGCHANNELSdrugchannels.netVisit source
- Reference 2STATISTAstatista.comVisit source
- Reference 3GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 4IQVIAiqvia.comVisit source
- Reference 5NACDSnacds.orgVisit source
- Reference 6AMERICANACTIONFORUMamericanactionforum.orgVisit source
- Reference 7CMScms.govVisit source
- Reference 8MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 9EXPRESS-SCRIPTSexpress-scripts.comVisit source
- Reference 10PWCpwc.comVisit source
- Reference 11PCMANETpcmanet.orgVisit source
- Reference 12DELOITTEdeloitte.comVisit source
- Reference 13AMERICANPROGRESSamericanprogress.orgVisit source
- Reference 14INVESTORSinvestors.cvshealth.comVisit source
- Reference 15CIGNAcigna.comVisit source
- Reference 16UNITEDHEALTHGROUPunitedhealthgroup.comVisit source
- Reference 17FTCftc.govVisit source
- Reference 18HEALTHAFFAIRShealthaffairs.orgVisit source
- Reference 19PRIMETHERAPEUTICSprimetherapeutics.comVisit source
- Reference 20KFFkff.orgVisit source
- Reference 21BENEFITNEWSbenefitnews.comVisit source
- Reference 22FIERCEPHARMAfiercepharma.comVisit source
- Reference 23MODERNHEALTHCAREmodernhealthcare.comVisit source
- Reference 243AXISADVISORS3axisadvisors.comVisit source
- Reference 25FDAfda.govVisit source
- Reference 26NCPANETncpanet.orgVisit source
- Reference 27GAOgao.govVisit source
- Reference 28PBMACCOUNTABILITYPROJECTpbmaccountabilityproject.orgVisit source
- Reference 29AHAaha.orgVisit source
- Reference 30AMA-ASSNama-assn.orgVisit source
- Reference 31DEAdea.govVisit source
- Reference 32CVSCAREMARKcvscaremark.comVisit source
- Reference 33OPTUMoptum.comVisit source
- Reference 34CDCcdc.govVisit source
- Reference 35ASPEaspe.hhs.govVisit source
- Reference 36NASHPnashp.orgVisit source
- Reference 37JUSTICEjustice.govVisit source
- Reference 38NCSLncsl.orgVisit source
- Reference 39BALLOTPEDIAballotpedia.orgVisit source
- Reference 40CODEScodes.ohio.govVisit source
- Reference 41CONGRESScongress.govVisit source
- Reference 42ATTORNEYGENERALattorneygeneral.ky.govVisit source
- Reference 43CONTENTcontent.naic.orgVisit source
- Reference 44ECec.europa.euVisit source
- Reference 45STATUTESstatutes.capitol.texas.govVisit source
- Reference 46OIGoig.hhs.govVisit source
- Reference 47LEGISlegis.la.govVisit source
- Reference 48WVLEGISLATUREwvlegislature.govVisit source